{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:09:30Z","timestamp":1792606170943,"version":"4.5.0"},"reference-count":52,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"8","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Aberrant expression of nectin-4 (N4) has been observed in several malignancies emerging as new target for antibody-drug conjugates, especially in urothelial carcinoma of the bladder (UBC). Limited data on N4 positivity in nonurothelial genitourinary (GU) cancers are available. This systematic-review aimed to investigate N4 positivity among GU malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>A systematic literature review was performed on March 2023 using PubMed, MEDLINE, and Embase databases according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Protocol was amended to incorporate a new updated search on March 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Twenty-five studies evaluating N4 positivity in GU tumors were included, 14 on UBC, three on upper tract urothelial carcinoma (UTUC), six on histologic subtypes (HS) and divergent histology of the bladder, one on papillary renal cell carcinoma (pRCC), one in chromophobe RCC (chRCC), two on penile cancer, one in prostate cancer (PCa). Among UBC, stratifying per stage N4 positivity was higher in metastatic (weighted mean [WM], 90.8; range, 59.6-100) and in non\u2013muscle-invasive (WM, 87.4; range, 86.7-88.3) than in muscle-invasive UC (WM, 83.1; range, 68.2-100). The N4 positivity of UBC was higher than UTUC (WM, 62.9; range, 44.4-65.7). Immunohistochemistry N4 positivity was reported to be lower in non-UC malignancies, including pRCC (WM, 44.1; range, 44.1-44.1), HS (WM, 63.5; range, 0-100), PCa (WM0; range, 0-0), chRCC (WM, 18.5; range, 18.5-18.5), and penile cancer (WM, 86.5; range, 61.4-98.3), compared with UBC overall (WM, 87.1; range, 59.6-100).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Non-UC malignancies seem to have a lower N4 positivity rate than UC. N4 positivity in bladder cancer appears to vary according to stage and presence of HS. The predictive and prognostic role of N4 must be further characterized in larger and prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/po-24-00470","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T15:59:28Z","timestamp":1733241568000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":14,"title":["Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3379-2644","authenticated-orcid":true,"given":"Emanuele","family":"Crupi","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy"},{"name":"Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9851-5162","authenticated-orcid":true,"given":"Tiago","family":"Costa de Padua","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Marandino","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7872-2650","authenticated-orcid":true,"given":"Giuseppe","family":"Fallara","sequence":"additional","affiliation":[{"name":"Department of Urology, IRCCS Istituto Europeo di Oncologia, IEO, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3873-7465","authenticated-orcid":true,"given":"Filippo","family":"Pederzoli","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Cimadamore","sequence":"additional","affiliation":[{"name":"Department of Medicine, Institute of Pathological Anatomy, University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele C.","family":"Goetz","sequence":"additional","affiliation":[{"name":"SDA Bocconi School of Management University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7109-2429","authenticated-orcid":true,"given":"Antonio","family":"Cigliola","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano A.","family":"Patan\u00e9","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1165-1776","authenticated-orcid":true,"given":"Chiara","family":"Mercinelli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1199-2338","authenticated-orcid":true,"given":"Valentina","family":"Tateo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0595-7165","authenticated-orcid":true,"given":"Andrea","family":"Salonia","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University, Milan, Italy"},{"name":"Department of Urology, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University, Milan, Italy"},{"name":"Department of Urology, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University, Milan, Italy"},{"name":"Department of Urology, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5444-5510","authenticated-orcid":true,"given":"Joshua J.","family":"Meeks","sequence":"additional","affiliation":[{"name":"Departments of Urology and Biochemistry, Molecular Genetics, Northwestern University, Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5723-1972","authenticated-orcid":true,"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9658-2206","authenticated-orcid":true,"given":"Omar","family":"Alhalabi","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3546-9928","authenticated-orcid":true,"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[{"name":"Department of Urology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3965-3394","authenticated-orcid":true,"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology Oncology, University of Washington, Seattle, WA"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-2756","authenticated-orcid":true,"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy"},{"name":"Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4185-2475","authenticated-orcid":true,"given":"Daniele","family":"Raggi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2021.5273"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174516"},{"key":"e_1_3_5_4_2","first-page":"8789","article-title":"High expression of Nectin-4 is associated with unfavorable prognosis in gastric cancer","volume":"15","author":"Zhang Y","year":"2018","unstructured":"Zhang Y, Zhang J, Shen Q, et al: High expression of Nectin-4 is associated with unfavorable prognosis in gastric cancer. Oncol Lett 15:8789-8795, 2018","journal-title":"Oncol Lett"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01983"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1313"},{"key":"e_1_3_5_7_2","first-page":"10089","article-title":"The prognostic role of expression of Nectin-4 in esophageal cancer","volume":"25","author":"Lin X","year":"2019","unstructured":"Lin X, Hu H, Pan Y, et al: The prognostic role of expression of Nectin-4 in esophageal cancer. Med Sci Monit Int Med J Exp Clin Res 25:10089-10094, 2019","journal-title":"Med Sci Monit Int Med J Exp Clin Res"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw678"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4175"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000938"},{"key":"e_1_3_5_11_2","unstructured":"Research C for DE and drug trials snapshots: PADCEV. FDA. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshots-padcev"},{"key":"e_1_3_5_12_2","unstructured":"Research C for DE and FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer. FDA. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic-urothelial-cancer"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02044"},{"key":"e_1_3_5_14_2","unstructured":"Rosenberg JE Milowsky M Ramamurthy C et al: LBA73\u2014Study EV-103 cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la\/mUC). https:\/\/oncologypro.esmo.org\/meeting-resources\/esmo-congress\/study-ev-103-cohort-k-antitumor-activity-of-enfortumab-vedotin-ev-monotherapy-or-in-combination-with-pembrolizumab-p-in-previously-untreated-c"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01643"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01140"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00094-2"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.106"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/XEB.0000000000000054"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.10.009"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-022-03328-1"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.858865"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.154072"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-021-02717-3"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.05.014"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1764"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155390"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09259-z"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-022-00940-w"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184411"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111547"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1159\/000535473"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-022-00558-2"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2022.12.008"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2023.10.003"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-5-13"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.652"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28299"},{"key":"e_1_3_5_40_2","article-title":"Occurrence of NECTIN4 amplification in solid tumors and enfortumab vedotin response in metastatic urothelial cancer","volume":"42","author":"Kl\u00fcmper N","year":"2024","unstructured":"Kl\u00fcmper N, Tran NK, Zschaebitz S, et al: Occurrence of NECTIN4 amplification in solid tumors and enfortumab vedotin response in metastatic urothelial cancer. J Clin Oncol 42, 2024 (suppl 4; abstr 673)","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad246"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3882"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.11.005"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-1140"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-024-01369-0"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/ilar.46.3.258"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1877-7"},{"key":"e_1_3_5_48_2","article-title":"Membranous expression of target protein is required for ADC response in urothelial cancer","author":"Kl\u00fcmper N","unstructured":"Kl\u00fcmper N, Br\u00e4gelmann J, Bahlinger V, et al: Membranous expression of target protein is required for ADC response in urothelial cancer. Eur Urol 10.1016\/j.eururo.2024.06.023 [epub ahead of print on July 31, 2024]","journal-title":"Eur Urol"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.02.001"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.3114"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0609"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.4596"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.14744\/nci.2023.36034"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-24-00470","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T08:51:45Z","timestamp":1734598305000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-24-00470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1200\/PO-24-00470"],"URL":"https:\/\/doi.org\/10.1200\/po-24-00470","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"2024-07-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2400470"}}